Zejula® (niraparib) – Indication update
December 8, 2022 - The FDA approved an update to GSK’s label for Zejula (niraparib), restricting the indication for maintenance treatment of patients with recurrent ovarian cancer to those with a germline BRCA mutation only.
Download PDF
